Access to Medicine Index 2022 ▶ Company report cards

RA N KSCO R E7

3.51

6 (2021)

Takeda Pharmaceutical Co, Ltd
Stock exchange: NYSE • Ticker: TAK • HQ: Tokyo, Japan • Employees: 47,347

PERFORMANCE IN THE 2022 INDEX
7th place. Takeda ranks among the top ten countries in
the Index. The company performs strongly in Governanceof Access and engages in high-quality capacity building
initiatives across all fields. Despite having a small pipeline, it

How score was achieved
4.43

Governance of Access
2.98

Research & Development

3.55

Product Delivery

also performs well in Research & Development, by applying

01

comprehensive access plans to all late-stage pipeline
candidates.

2

3

Average

Leader4

5

dates. The company also performs strongly in R&D capacity
Governance of Access: 2nd place. Takeda performs strongly

building. However, it has a small-sized priority pipeline com-in this area. It has an integrated access-to-medicine strategy

pared to its peers.

with direct board-level responsibility for access to medicine
and incentives for its senior executives, including the CEO,

Product Delivery: 7th place. Takeda performs well in this area.

and in-country and regional managers. It discloses outcomes

It leads in applying access strategies for healthcare practi-

of its access-to-medicine activities and has a robust set oftioner-administered products across all country income levels

compliance controls to mitigate the risk of non-compliance in

but it has a comparatively poor performance for sharing intel-

countries in scope of the Index.

lectual property assets, with no evidence of engaging in newagreements during the period of analysis. It has a strong per-Research & Development: 7th place. Takeda performs above

formance in supply chain capacity building and health systems

average in this area. It has a structured access planning frame-

strengthening but shows average performance in building

work and applies this to all of its late-stage pipeline candi-

manufacturing capacity.

OPPORTUNITIES FOR TAKEDACHANGES SINCE THE 2021 INDEX

Expand the geographic coverage of project-specific access plans for non-

• The launch of Corporate Philosophy Dashboard, including the launchcommunicable diseases. Takeda has comprehensive access plans in placeof the Growth and Emerging Market Transformation and Aspiration

for all late-stage R&D projects analysed. The company can increase theDashboard which provides a framework of measuring progress against

number of countries included in these plans. For example, the access planfor mobocertinib (Exkivity™) for lung cancer can be expanded to include
more low- and lower-middle income countries.

priorities included access metrics.
• Successful completion of an innovative digital authentication technology
pilot in Kenya which will allow the authentication of Takeda products andnow preparing for launch readiness in higher risk markets.

Expand registration of cancer products. Takeda has four on-patent• Evaluating a novel field and rapid analytical technology based on time-cancer medicines in its portfolio, including non-Hodgkin lymphoma

domain nuclear magnetic resonance (TD-NMR) that has been adapted

treatment brentuximab vedotin (Adcetris®). This product has been filed

for testing biologics and vaccines counterfeit suspects to provide

in 21 countries in scope of the Index, including three countries with a highimmediate results.

burden of non-Hodgkin lymphoma. The company can further expand the• Sought regulatory authorization for its dengue vaccine candidate (TAK-registration of this product, especially in countries where the burden of003). Takeda is participating in the EMA’s first-ever parallel assessment

non-Hodgkin lymphoma is the highest, such as Myanmar, Afghanistan andof a medicinal product for use in the European Union (EU), and throughSuriname.

the EU-M4all procedure for countries outside of the EU.
• Joined the Antimicrobial Resistance (AMR) action fund, which was

Expand the use of tools to assess patients' ability to pay and determine
differential prices to more products and countries. Takeda developed asophisticated Patient Assistance Tool to assess individual patients' ability

established to support the clinical development of new antimicrobial
agents and to achieve a sustainable antimicrobial market.
• Scaled up the Blueprint for Innovative Healthcare Access initiative

to pay. The company can apply this tool to more of its products, such as its

concept to Nigeria in partnership with BIO Ventures for Global Healthlung cancer treatment brigatinib (Alunbrig®), in countries where the tool is(BVGH) to build diagnostic and treatment capacity and in Uganda andalready being applied for other products. The patient assistance tool andintra-country pricing strategies can be applied in more countries in scopewith a high burden of lung cancer such as China and Thailand.

Tanzania with the International Cancer Institute (ICI).
• Partnered with UNITAR and the local authorities of Rwanda and South
Africa to launch the new Value-based Healthcare (VBHC) Hub, whichfacilitates locally led initiatives that will promote and advance theimplementation of VBHC models in low-income and resource-limited
settings.
• Takeda takes a co-leadership role in the Corona Accelerated R&D in
Europe (CARE) programme.

77

All companies were assessed based on
information that was valid in the latest
period of analysis (ending at 31 May2022). This data was either submitted bycompanies, found in the public domain or
was accessible through other sources.

The term LMICs is used to denote all
low- and middle-income countries inscope of the Index, except when analysing
companies’ access strategies where
the use of LMIC refers to lower-middle
income countries as per the World Bank

income groups classification. Likewise, theterms LIC and UMIC refer to low income
countries and upper-middle income
countries.

Access to Medicine Index 2022 ▶ Company report cards

SALES AND OPERATIONSBusiness segments: Pharmaceuticals.

Takeda's products are sold in 37 out of 108

Therapeutic areas: Oncology, Rare Diseases,

countries in scope of the Index. Takeda has

Revenue by segment (2021) – in JPY

Neuroscience, Gastroenterology (GI) and Plasma

sales offices in 21 countries, and sells via

Pharmaceuticals

Derived Therapies.

suppliers and/or pooled procurement in an		Product categories: Innovative medicines andadditional 16 countries.

Total

3,569.01 bn
3,569.01 bn

vaccines.
M&A news: In March 2021, Takeda announced
it would acquire Maverick Therapeutics for
USD 525 million. Takeda acquired GammaDelta
Therapeutics in November 2021.
Sales by geographic region
Revenue (Bn JPY)

Sales in countries in scope

4,000
3,000
2,000
1,000
0

In scope, has sales offices
In scope, any sales

2017

2018

Rest of world

In scope, no sales

Europe/Canada

Not in scope

2019

2020

Asia (ex Japan)
Japan

2021
Latin America

Russia/CIS

USA

SAMPLE OF PIPELINE AND PORTFOLIO ASSESSED BY THE INDEXPIPELINE for diseases in scope

PORTFOLIO as selected for analysis by the Index

Takeda has a total of 21 R&D projects in scope with 11 of these projects tar-

Takeda has 16 medicines in scope, 12 of which are on patent, and one vac-geting priority diseases. The other ten R&D projects target other diseases

cine. 42% of these medicines (5) are on the WHO EML. The off-patentin scope. Of the projects targeting priority diseases, the focus is on coro-

medicines target non-communicable diseases (NCDs) such as cancer (1),naviral diseases (6). Of the projects targeting other diseases in scope, thecardiovascular diseases (2) and kidney diseases (1). The on-patent med-focus is on oncology (7).

icines target NCDs (12) such as diabetes (5), cancer (4), cardiovascular

Four R&D projects are in late-stage development that target either a pri-diseases (2) and kidney diseases (1). Takeda's preventative vaccine targets

ority disease (1) or address a public health need in LMICs (3).* Evidence oflower respiratory infections.

access planning was in place for 100% of these projects.

21 projects in the pipeline

17 products as selected for analysis by the Index†

9

Neglected tropical 0Maternal and neonatal 0

Maternal and neonatal 0

10Multiple categories 0
0

20
30
40
50
projects in the pipeline

0

1

8

1

0

0

1

0

11

Contraceptives

Addresses needs of LMICs*

1

0

2

1

0

4

Diagnostics

Other projects in scope

3

3

0

0

0

6

Other

*50 diseases and 243 product gaps inscope have been established as a priority by global health stakeholders. For
other diseases, the Index used a set of criteria to determine which projects in thepipeline offer a clear public health benefit to patients in LMICs. Only projects inthe clinical phase of development were
included for this analysis.
**Neglected tropical diseases, while also
communicable, are highlighted separately
throughout the Index.
***Other includes projects that have atechnical lifecycle and projects that fol-

‡

Total

0

Total

1

0

Other***

0Registration/approval

4

1

Phase III12

1

Phase II

11

3

Phase I1

off patent

Pre-clinical

Medicines on patent

Vaccines

Targets established R&D priorities

78

20
30
40
50
products on the market

Breakdown of products

Discovery

Breakdown of projects

10

Other

10

WHO EDL

016

Non-communicableMultiple categories 0

Non-EML

Non-communicable1

Communicable**2

WHO EML

Communicable**
Neglected tropical000

low a different development cycle (e.g.
diagnostics).
†Products included in the analysis wereselected using a set of criteria determinedby stakeholder consensus.
‡Other includes vector control products.

0

Access to Medicine Index 2022 ▶ Company report cards

Takeda Pharmaceutical Co, Ltd

GOVERNANCE OF ACCESSRANK 2SCORE 4.43

Has an access-to-medicine strategy with meas-ency by consistently sharing the outcomes offraud-specific risk assessment, country risk-based

urable objectives, integrated within its overall

its access-to-medicine activities in a centralised

assessment, a continuous system to monitor

corporate strategy. Takeda performs strongly.

manner within its Access to Medicines Progress

activities, audits (both internal and external, cov-

Its strategy, called The Corporate Philosophy,

Report and its Annual Integrated Report.

ering third parties and in all countries where it

aims to increase sustainable access of innova-

operates) and has formal processes to ensure

tive medicines globally and covers all therapeutic

Performs above average in responsible pro-third-party compliance with company standards

areas in which the company is involved. The high-motional practices. Takeda’s sales agents arewhich has recently been updated and enhanced.

est responsibility for access lies directly with thenot solely incentivised on sales volume tar-

No breaches in countries in scope of the Index

board, namely the CEO of the Takeda Executive

gets. Employee KPIs are based on company

were publicly found in the period of analysis.

Team.

or global KPIs which are then passed onto thebusiness unit or function. It does not publicly dis-Publicly supports the Doha Declaration on

Provides evidence of financial and non-financial

close information related to transfers of values

TRIPS and Public Health. Takeda publicly sharesaccess-related incentives at the executive level.

to healthcare professionals (HCPs) in the bulk of

support of the Doha Declaration on TRIPS and

Takeda performs strongly. It incentivises its sen-countries in scope of the Index (e.g., payments for

Public Health, but expresses reservations on its

ior executives and in-country managers in Growthattending events or promotional activities), unlessprovisions, stating that it does not view compul-

and Emerging Markets units to take action onrequired by law or by local regulations. However,sory licensing as a sustainable solution and should

access to medicine with financial and non-finan-

Takeda reports that it has standard operating

only be use in exceptional circumstances and ascial rewards. The CEO also has access-related

procedures to control HCP engagement in alla last resort. There is evidence of industry asso-

incentives.

countries in scope of the Index and has imple-

ciation lobbying on IP and the usage of TRIPS

mented automation/digitalisation initiatives toflexibilities, namely of compulsory licensing, byincrease controls around HCP activities.

national governments in some countries in scope

Publicly discloses outcomes of its
access-to-medicine activities. Takeda performsof the Index. As a member of the industry asso-

strongly in transparency of access activities.

Has a robust set of compliance controls to

ciation, Takeda, like all other member companies

It publicly discloses commitments, measura-

ensure that governance efforts are not under-in scope of the Index, is by default connected toble goals, objectives and targets for improving

mined by non-compliant or corrupt activities.

this activity.

access to medicine in countries in scope of theTakeda performs strongly, demonstrating evi-

Index. It facilitates accountability and transpar-

dence of all components looked for by the Index:

RESEARCH & DEVELOPMENTRANK 7SCORE 2.98

Access planning processes encompass all pro-

The plan considers innovative methods to ensure

All five R&D capacity building initiatives

jects in the pipeline. Takeda has a structured

availability, affordability and supply.

included for analysis meet all Good PracticeStandards. Takeda leads in this area. The number

process in place to develop access plans during R&D. The process is intended to be appliedSome projects address a public health need in

of initiatives meeting all inclusion criteria is higher

to all R&D projects (both in-house and collabora-

LMICs,* with 100% (3/3) of late-stage projects

than average and more initiatives meet all Goodtive) in the company's pipeline. In general, Takeda

covered by access plans. In this analysis, Takeda

Practice Standards than what is average for thisbegins developing access plans for R&D projects

has three late-stage R&D projects that target

indicator. Takeda builds R&D capacity through thein Phase II or earlier of clinical development.

a disease and/or product gap not yet estab-following initiatives:lished as a priority by global health stakeholders.

- Strengthening clinical trial capacity in LMICs

A small-sized priority R&D pipeline compared

These projects are all deemed by the Index towith BIO Ventures for Global Health.

to its peers. Takeda has 11 projects, including

offer a clear public health benefit for people liv-

- Clinical care and lab capacity building with

one late-stage candidate in its pipeline that tar-ing in LMICs.* These projects have clinical trials

Partners in Health, AMPATH, Foundation for

get a priority product gap. These projects focus

in countries in scope of the Index or the projectCancer Care Tanzania (FCCT) and Healthcare

on communicable diseases including coronavi-

is a first-in-formulation treatment. They focus onPartners for Access (HPA).

ral diseases, Zika, malaria, dengue, chikungunyacancer and epilepsy. Takeda provides evidence- Instrumental Access Program with Seeding

and tuberculosis. There is evidence of an accessof access plans for all three late-stage projects.

Labs to strengthen local research and diagnos-

plan for Takeda’s late-stage candidate targeting

These access plans mainly focus on registration

tic capabilities.

a priority product gap. This plan for the dengue

preparation and continuous supply.

- ReGRoW (Repurposing Grants for the Rest of

vaccine candidate (TAK-003) is currently under-

79

the World) program with Cures Within Reachgoing regulatory review in the European Union

Does not publicly disclose R&D investment

fosters repurposing research to address healththrough the EU-Medicines for all (EU-M4all) pro-data disaggregated by disease category, prod-

inequities and improve access to medicines.

cedure which intends to facilitate patient access

uct type or phase of development. However,to essential medicines or vaccines that prevent

Takeda does disclose fully disaggregated R&D

or treat diseases of major public health interest.

investment data to Policy Cures Research.

*50 diseases and 243 product gaps inscope have been established as a priority
by global health stakeholders. For otherdiseases, the Index used a set of criteria
to determine which projects in the pipeline offer a clear public health benefit topatients in LMICs. Projects in the clinicalphase of development were included forthis analysis.

Access to Medicine Index 2022 ▶ Company report cards

PRODUCT DELIVERYRANK 7SCORE 3.55

Public commitment not to enforce patents inon the National List of Essential Medicines andachieve “healthy villages” by reducing preventablecountries in scope. Takeda publicly pledges tomore than 75% of patients can access it. Takeda

deaths among mothers and children by strength-

neither file for nor enforce patents. This commit-

provides evidence of patient reach.

ening training for 1,400 community healthment applies in Least Developed Countries andworkers and providing approximately 500,000
Has access strategies for its self-administeredpeople in local communities with healthcare-re-products for some countries in scope of thislated knowledge and services to prevent disease

Publicly discloses information on patent sta-analysis. Takeda has an average performanceand protect lives.

tus. Like most of its peers, Takeda discloses thein this area. The company provides examples

patent statuses for small molecules in scope viaof access strategies in countries of all assessed

Has engaged in scaling up one inclusive busi-

the Pat-INFORMED database. Takeda discloses

income levels (UMIC, LMIC, LIC) for two of theness model but has not shown evidence ofpatent information, including filing date, grant

five products assessed. It makes efforts to reach

its involvement in piloting any new inclusive

number, grant date and jurisdiction.

additional patients through pricing strategies

business models that meet all inclusion cri-that consider payers' ability to pay and patientteria. Takeda performs average in the use of

Performs below average in terms of sharing

affordability programmes (PAPs). For example,

inclusive business models aimed at meeting theintellectual property (IP) assets with third-

in Indonesia, for brigatinib (Alunbrig®) Takeda

access needs of populations at the base of theparty researchers. Takeda does not reportapplies an inter-country tiered pricing strategy.

income pyramid (including other underservedon any new IP-sharing agreements with public

In addition, it launched two projects: the Market

populations) in LMICs. Blueprint for Innovative

research institutions or drug discovery initiatives

Access Scheme programme in which patients

Healthcare Access in Rwanda, Tanzania, Uganda

established during the current analysis period

get fixed price reductions based on theirand Nigeria aims to save and improve the lives

that meet all inclusion criteria for evaluation. The

healthcare practitioner's discretion, and a PAP

of patients with cancer and other non-commu-

company does have existing agreements of thiswhich provides further cost reduction based on

nicable diseases using a practical framework tonature in place that were established before thea patient affordability assessment. Forecasted

sustainably strengthen healthcare systems at acurrent period of analysis and meet all inclusion

patient reach for the programme is available. In

local level and provide innovative affordability

criteria for evaluation.

addition, the company provides evidence of how

programmes.

LICs.

patient reach has been increased through the
No use of licensing agreements. Takeda does

approaches used.

Performs above average in terms of ensuring continuous supply of medicines in LMICs.

not engage in voluntary licensing for products inscope of the Index. It publicly states it would con-The one manufacturing capacity building ini-

Takeda is involved in technology transfers withsider granting non-exclusive voluntary licences intiative included for analysis meets all Good

third-party manufacturers in LMICs, and has a sys-certain circumstances.

Practice Standards. Takeda's performancetem in place to work with relevant stakeholders

is average in this area. The number of initia-

to communicate issues that may affect the supply

Filed to register new products in seven coun-tives meeting all inclusion criteria is lower thanchain, works with several active pharmaceuticaltries in scope on average. Takeda did not

average and fewer initiatives meet all Good

ingredient suppliers, manages a buffer stock ofdisclose evidence of filing for registration any

Practice Standards (GPS) than what is average

relevant products and is involved in supply chainof its new products in more than half of the top

for this indicator. From 2017 until 2021, Takeda

capacity building initiatives in LMICs.

ten high burden countries. Among old prod-

was involved in a partnership with Biological E.

ucts, its most widely filed is brentuximab vedotin

Limited in India where the company agreed to

Has a policy for reporting substandard and fal-

(Adcetris®), for the treatment of non-Hodg-

transfer technology to manufacture affordable

sified (SF) medicines in countries in scope ofkin lymphoma, is filed in 21 countries within the

combination vaccines for measles. This initiative

the Index in less than ten days. Takeda has ascope of the Index, including three high burden

meets all GPS.

policy expecting reporting of SF medicines tocountries (Ecuador, Peru and Ukraine).

national health authorities and the WHO within
All five supply chain capacity building initiatives

seven days. It provides evidence of shortened

Takeda is not eligible for assessment of supra-

included meet all Good Practice Standards.

reporting timeframes for cases which only require

nationally procured products.

Takeda is one of the leaders in this area. The

visual inspection to be confirmed.

number of initiatives meeting all inclusion criteria
Has access strategies for all its healthcare

is higher than average and more initiatives meet

Donates in response to expressed need andpractitioner-administered products in scope

all GPS than what is average for this indicator.

monitors delivery. Takeda has public policiesof this analysis. Takeda is leading in this area.

For example, Takeda’s five-year partnership withand supply processes in place to ensure ad hoc

For the two products assessed, the company

the World Food Programme (WFP) aims to makedonations are carried out rapidly in response toprovides examples of access strategies which

health systems and public health supply chainsexpressed need, and it monitors the delivery of

consider affordability in countries of all assessedmore resilient and enhance targeted countries'

donations until they reach the patient.

income levels (UMIC, LMIC, LIC). It makes efforts

ability to absorb and respond to health emergen-to reach additional patients using tiered inter-cies and pandemic preparedness. This initiative

Has no long-term donation programmes forcountry pricing strategies and intra-country

meets all GPS.

neglected tropical diseases or malaria thatare eligible for analysis under this indicator.

pricing strategies through patient assistance80

programmes. For example, Takeda evidenced an

All five health systems strengthening initiatives

However, the company is engaged in anotherincrease in patient reach of 41% through patient

included for analysis meet all Good Practice

structured donation programme: the Max Accessassistance programmes for Adcetris in Thailand

Standards. Takeda is one of the leaders in thisSolutions whereby it donates ponatinib (Iclusig®)

and the Philippines and the company developed aarea. The number of initiatives meeting all inclu-

for chronic myeloid leukaemia in 17 countries

pricing strategy that considers patients' ability tosion criteria is higher than average and moresince 2015.

pay for its oncology medicine leuprolide acetate

initiatives meet all GPS than what is average for(Enantone®) in Thailand. The product is listed

this indicator. For example, Healthy Village aims to